Developer docs
API playgroundTry for free, no card

Search company profiles

Alterome Therapeutics

Full company profile

uuid0000kxa

Namestring
Alterome Therapeutics
Legal namestring
Alterome Therapeutics, Inc.
Websiteurl
alterome.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Alterome Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego, California, developing alteration-specific targeted therapies for genetically defined oncology populations. The company's discovery engine is "The Kraken," a proprietary computational chemistry platform that combines structure-guided drug design with machine learning to engineer small molecules that selectively address specific oncogenic mutations rather than broad pathways. This mutation-specific approach is intended to expand the therapeutic index relative to traditional targeted oncology agents.

The pipeline comprises two first-in-class clinical-stage candidates, both in Phase 1/1b development. ALTA2618 is a mutation-specific AKT1 E17K inhibitor targeting a defined subset of solid tumors driven by that activating mutation, with first patient dosed in October 2024. ALTA3263 is positioned as a first-and-best-in-class pan-KRAS dual ON/OFF inhibitor, with first patient dosed in March 2025. The scientific advisory board includes investigators from Memorial Sloan Kettering, MD Anderson, Massachusetts General Hospital/Harvard, and Scripps, and leadership includes Board Chair Rich Heyman, CEO Jung Choi (appointed April 2025), and CMO Leonardo Faoro (appointed February 2026).

Alterome is pre-revenue and funds operations entirely through equity capital. Total funding exceeds $231 million across a $64 million Series A (January 2022), a $35 million Series A2 (November 2022), and a $132 million Series B (April 2024) led by Goldman Sachs Alternatives, with participation from OrbiMed, Vida Ventures, Nextech Invest, Driehaus Capital, Canaan Partners, Blue Owl, Invus, Boxer Capital, Colt Ventures, and Digitalis Ventures. In January 2025 the company added a partnership with Imagenomix Corp to apply AI tooling to clinical-trial operations. The company's business model is to advance mutation-specific oncology candidates through early-stage clinical proof-of-concept with the intent of partnering or further developing high-value assets; commercialization is not yet in scope.

Short descriptiontext

Alterome Therapeutics is a clinical-stage, San Diego-based precision oncology company that uses its proprietary Kraken computational chemistry and machine learning platform to develop mutation-specific small-molecule inhibitors, currently advancing two Phase 1/1b assets targeting AKT1 E17K and pan-KRAS oncology populations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology, targeted cancer therapy, small molecule drugs, AKT1 inhibitors, KRAS inhibitors
Industry1 code
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Precision Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pipeline Development and Future Product Revenue
TypeOne Time License
Description

Pre-revenue clinical-stage company developing a pipeline of targeted oncology therapies. Revenue will be generated through commercialization of approved drug products following successful clinical development and regulatory approval. The company has raised over $231 million in venture capital funding to support clinical-stage development of ALTA2618 and ALTA3263.

alterome.com
2Potential Licensing and Partnership Deals
TypeLicensing Royalties
Description

Biopharmaceutical companies may generate revenue through licensing agreements, co-development partnerships, or acquisition transactions as pipeline programs advance through clinical development toward regulatory approval.

pharmiweb.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alterome Therapeutics is a clinical-stage precision oncology company developing alteration-specific small molecule targeted therapies for validated oncogenic drivers. Its pipeline includes two first-in-class drug candidates in Phase 1/1b trials: ALTA2618, a mutation-selective AKT1 E17K inhibitor for AKT-driven solid tumors, and ALTA3263, a pan-KRAS dual ON/OFF-state inhibitor for KRAS-mutant solid tumors, both designed using The Kraken computational chemistry platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ALTA2618 targets up to 90% of AKT-activated cancers driven by the AKT1 E17K mutation while potentially eliminating AKT2-driven hyperglycemia toxicity seen with pan-AKT inhibitors
+2 more records
Product overview1 text field

Alterome Therapeutics is a clinical-stage precision oncology company developing a pipeline of next-generation, small molecule targeted therapies for cancer treatment. The company's portfolio consists of two clinical-stage drug candidates: ALTA2618 (a mutation-specific AKT1 E17K inhibitor for AKT-driven cancers) and ALTA3263 (a pan-KRAS dual ON/OFF inhibitor for KRAS-driven cancers). Both programs leverage the company's structure-guided drug discovery approach to develop alteration-specific therapeutics that target disease-driving genetic mutations while sparing wild-type proteins, aiming to overcome the safety and efficacy limitations of earlier targeted therapies.

Product and service2 records
1ALTA2618
CategoryDrug Candidate
Description

A first-in-class, mutation-specific inhibitor of AKT1 E17K designed to treat AKT-driven cancers including breast, endometrial, and prostate cancers. Engineered for selectivity, potency, and a broad therapeutic index, it targets the mutant protein while sparing wild-type AKT isoforms and is in Phase 1/1b clinical development.

2ALTA3263
CategoryDrug Candidate
Description

A first-and-best-in-class pan-KRAS dual ON/OFF inhibitor designed for broad, durable, and tolerable inhibition of KRAS-driven cancers. It targets KRAS while sparing HRAS and NRAS, demonstrating sub-1nM potency across over 90% of KRAS mutations including G12D, G12V, and wild-type KRAS, and is in Phase 1/1b clinical development.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierSupportingTypeTechnology or Integration
Description

Alterome partnered with Imagenomix Corp. in January 2025 to enhance precision oncology clinical trials with AI technology. This partnership aims to improve clinical trial efficiency and patient selection through artificial intelligence integration.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage precision oncology company developing medicines targeting the chromatin regulatory system. Comparable as a platform-driven precision oncology biotech, though targeting different oncogenic mechanisms.

TypeBroad incumbent
Description

Large biopharmaceutical company with Lumakras (sotorasib), the first FDA-approved KRAS G12C inhibitor. Major established incumbent in the KRAS oncology space that Alterome's pan-KRAS program must differentiate against.

TypeDirect peer
Description

Clinical-stage precision oncology company focused on KRAS-driven cancers with allosteric inhibitors. Comparable to Alterome's mutation-selective KRAS approach; CMO Leonardo Faoro was previously CMO at Quanta.

TypeDirect peer
Description

Developed Krazati (adagrasib), a KRAS G12C inhibitor, now under Bristol Myers Squibb following acquisition. Directly comparable to Alterome's ALTA3263 pan-KRAS inhibitor as a competitor in the KRAS precision oncology space.

TypeDirect peer
Description

Clinical-stage precision oncology company developing RAS-targeted therapies, including the pan-RAS(ON) inhibitor RMC-6236. Directly comparable to Alterome as a competing developer of KRAS-targeted small molecules with a structure-based discovery approach.

TypeDirect peer
Description

Clinical-stage precision oncology company focused on the RAS/MAPK pathway. Highly comparable to Alterome's KRAS and AKT targeting strategy with multiple programs targeting oncogenic drivers in the same signaling cascade.

TypeDirect peer
Description

Clinical-stage precision oncology company combining computational approaches with structural biology to develop targeted therapies. Comparable technology approach and oncology focus to Alterome's The Kraken platform.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small molecule therapies against high-value oncogenic targets, including PI3Kα and others. Closely comparable to Alterome's alteration-specific approach targeting validated oncogenic drivers.

TypeEmerging player
Description

Computational drug discovery platform company with growing internal pipeline including precision oncology programs. Comparable to Alterome's structure-guided, ML-enabled small molecule discovery approach.

TypeEmerging player
Description

Clinical-stage precision oncology company developing therapies targeting resistance mechanisms in cancer. Comparable biotech-stage peer with overlapping investor base (Alterome board member Dominic Piscitelli is CFO of ORIC).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alterome Therapeutics

Precision Oncology Therapeuticsalterome.com

Alterome Therapeutics is a clinical-stage, San Diego-based precision oncology company that uses its proprietary Kraken computational chemistry and machine learning platform to develop mutation-specific small-molecule inhibitors, currently advancing two Phase 1/1b assets targeting AKT1 E17K and pan-KRAS oncology populations.

What Alterome Therapeutics does

Alterome Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego, California, developing alteration-specific targeted therapies for genetically defined oncology populations. The company's discovery engine is "The Kraken," a proprietary computational chemistry platform that combines structure-guided drug design with machine learning to engineer small molecules that selectively address specific oncogenic mutations rather than broad pathways. This mutation-specific approach is intended to expand the therapeutic index relative to traditional targeted oncology agents.

The pipeline comprises two first-in-class clinical-stage candidates, both in Phase 1/1b development. ALTA2618 is a mutation-specific AKT1 E17K inhibitor targeting a defined subset of solid tumors driven by that activating mutation, with first patient dosed in October 2024. ALTA3263 is positioned as a first-and-best-in-class pan-KRAS dual ON/OFF inhibitor, with first patient dosed in March 2025. The scientific advisory board includes investigators from Memorial Sloan Kettering, MD Anderson, Massachusetts General Hospital/Harvard, and Scripps, and leadership includes Board Chair Rich Heyman, CEO Jung Choi (appointed April 2025), and CMO Leonardo Faoro (appointed February 2026).

Alterome is pre-revenue and funds operations entirely through equity capital. Total funding exceeds $231 million across a $64 million Series A (January 2022), a $35 million Series A2 (November 2022), and a $132 million Series B (April 2024) led by Goldman Sachs Alternatives, with participation from OrbiMed, Vida Ventures, Nextech Invest, Driehaus Capital, Canaan Partners, Blue Owl, Invus, Boxer Capital, Colt Ventures, and Digitalis Ventures. In January 2025 the company added a partnership with Imagenomix Corp to apply AI tooling to clinical-trial operations. The company's business model is to advance mutation-specific oncology candidates through early-stage clinical proof-of-concept with the intent of partnering or further developing high-value assets; commercialization is not yet in scope.

Alterome Therapeutics firmographics

Firmographics
Name
Alterome Therapeutics
Legal name
Alterome Therapeutics, Inc.
Website
https://alterome.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Alterome Therapeutics is a clinical-stage, San Diego-based precision oncology company that uses its proprietary Kraken computational chemistry and machine learning platform to develop mutation-specific small-molecule inhibitors, currently advancing two Phase 1/1b assets targeting AKT1 E17K and pan-KRAS oncology populations.
Ownership category
akta.pro rank

Alterome Therapeutics industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals

Keywords

  • Precision oncology
  • Targeted cancer therapy
  • Small molecule drugs
  • AKT1 inhibitors
  • KRAS inhibitors

Where Alterome Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Alterome Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pipeline Development and Future Product Revenue: Pre-revenue clinical-stage company developing a pipeline of targeted oncology therapies. Revenue will be generated through commercialization of approved drug products following successful clinical development and regulatory approval. The company has raised over $231 million in venture capital funding to support clinical-stage development of ALTA2618 and ALTA3263.
  2. Potential Licensing and Partnership Deals: Biopharmaceutical companies may generate revenue through licensing agreements, co-development partnerships, or acquisition transactions as pipeline programs advance through clinical development toward regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Alterome Therapeutics product offering

Product offering

Core offering

Alterome Therapeutics is a clinical-stage precision oncology company developing alteration-specific small molecule targeted therapies for validated oncogenic drivers. Its pipeline includes two first-in-class drug candidates in Phase 1/1b trials: ALTA2618, a mutation-selective AKT1 E17K inhibitor for AKT-driven solid tumors, and ALTA3263, a pan-KRAS dual ON/OFF-state inhibitor for KRAS-mutant solid tumors, both designed using The Kraken computational chemistry platform.

Product overview

Alterome Therapeutics is a clinical-stage precision oncology company developing a pipeline of next-generation, small molecule targeted therapies for cancer treatment. The company's portfolio consists of two clinical-stage drug candidates: ALTA2618 (a mutation-specific AKT1 E17K inhibitor for AKT-driven cancers) and ALTA3263 (a pan-KRAS dual ON/OFF inhibitor for KRAS-driven cancers). Both programs leverage the company's structure-guided drug discovery approach to develop alteration-specific therapeutics that target disease-driving genetic mutations while sparing wild-type proteins, aiming to overcome the safety and efficacy limitations of earlier targeted therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • ALTA2618 A first-in-class, mutation-specific inhibitor of AKT1 E17K designed to treat AKT-driven cancers including breast, endometrial, and prostate cancers. Engineered for selectivity, potency, and a broad therapeutic index, it targets the mutant protein while sparing wild-type AKT isoforms and is in Phase 1/1b clinical development.
  • ALTA3263 A first-and-best-in-class pan-KRAS dual ON/OFF inhibitor designed for broad, durable, and tolerable inhibition of KRAS-driven cancers. It targets KRAS while sparing HRAS and NRAS, demonstrating sub-1nM potency across over 90% of KRAS mutations including G12D, G12V, and wild-type KRAS, and is in Phase 1/1b clinical development.

Quantifiable outcome

  • ALTA2618 targets up to 90% of AKT-activated cancers driven by the AKT1 E17K mutation while potentially eliminating AKT2-driven hyperglycemia toxicity seen with pan-AKT inhibitors
  • +2 more outcomes

Companies that use Alterome Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Alterome Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Alterome Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Imagenomix Corp.supportingTechnology or IntegrationAlterome partnered with Imagenomix Corp. in January 2025 to enhance precision oncology clinical trials with AI technology. This partnership aims to improve clinical trial efficiency and patient selection through artificial intelligence integration.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Alterome Therapeutics competitors and assessment

Company assessment

Emerging players

  • Foghorn Therapeutics: Clinical-stage precision oncology company developing medicines targeting the chromatin regulatory system. Comparable as a platform-driven precision oncology biotech, though targeting different oncogenic mechanisms.
  • Schrödinger: Computational drug discovery platform company with growing internal pipeline including precision oncology programs. Comparable to Alterome's structure-guided, ML-enabled small molecule discovery approach.
  • ORIC Pharmaceuticals: Clinical-stage precision oncology company developing therapies targeting resistance mechanisms in cancer. Comparable biotech-stage peer with overlapping investor base (Alterome board member Dominic Piscitelli is CFO of ORIC).

Broad incumbents

  • Amgen: Large biopharmaceutical company with Lumakras (sotorasib), the first FDA-approved KRAS G12C inhibitor. Major established incumbent in the KRAS oncology space that Alterome's pan-KRAS program must differentiate against.

Direct peers

  • Quanta Therapeutics: Clinical-stage precision oncology company focused on KRAS-driven cancers with allosteric inhibitors. Comparable to Alterome's mutation-selective KRAS approach; CMO Leonardo Faoro was previously CMO at Quanta.
  • Mirati Therapeutics (Bristol Myers Squibb): Developed Krazati (adagrasib), a KRAS G12C inhibitor, now under Bristol Myers Squibb following acquisition. Directly comparable to Alterome's ALTA3263 pan-KRAS inhibitor as a competitor in the KRAS precision oncology space.
  • Revolution Medicines: Clinical-stage precision oncology company developing RAS-targeted therapies, including the pan-RAS(ON) inhibitor RMC-6236. Directly comparable to Alterome as a competing developer of KRAS-targeted small molecules with a structure-based discovery approach.
  • Erasca: Clinical-stage precision oncology company focused on the RAS/MAPK pathway. Highly comparable to Alterome's KRAS and AKT targeting strategy with multiple programs targeting oncogenic drivers in the same signaling cascade.
  • Relay Therapeutics: Clinical-stage precision oncology company combining computational approaches with structural biology to develop targeted therapies. Comparable technology approach and oncology focus to Alterome's The Kraken platform.
  • Scorpion Therapeutics: Clinical-stage precision oncology company developing small molecule therapies against high-value oncogenic targets, including PI3Kα and others. Closely comparable to Alterome's alteration-specific approach targeting validated oncogenic drivers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Alterome Therapeutics social profiles

Digital presence

Alterome Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alterome Therapeutics leadership team

Management profile

Number of profiles

Profiles21 records

Alterome Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alterome Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alterome Therapeutics

What does Alterome Therapeutics do?

Alterome Therapeutics is a clinical-stage precision oncology company developing alteration-specific small molecule targeted therapies for validated oncogenic drivers. Its pipeline includes two first-in-class drug candidates in Phase 1/1b trials: ALTA2618, a mutation-selective AKT1 E17K inhibitor for AKT-driven solid tumors, and ALTA3263, a pan-KRAS dual ON/OFF-state inhibitor for KRAS-mutant solid tumors, both designed using The Kraken computational chemistry platform.

Is Alterome Therapeutics a public or private company?

Alterome Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Alterome Therapeutics founded?

Alterome Therapeutics was founded in 2022. It employs 11 to 50 people.

Where is Alterome Therapeutics based?

Alterome Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Alterome Therapeutics make money?

Two revenue lines are on record. Pipeline Development and Future Product Revenue is the primary driver. The others are potential Licensing and Partnership Deals.

Who are Alterome Therapeutics's main competitors?

Emerging players on record are Foghorn Therapeutics, Schrödinger and ORIC Pharmaceuticals. Amgen is listed as a broad incumbent. Direct peers are Quanta Therapeutics, Mirati Therapeutics (Bristol Myers Squibb), Revolution Medicines, Erasca, Relay Therapeutics and Scorpion Therapeutics.

Does Alterome Therapeutics have an API?

No public API is recorded for Alterome Therapeutics.

What industry is Alterome Therapeutics in?

Alterome Therapeutics's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogAlterome Therapeutics to Participate in November Investor ConferencesAlterome Therapeutics announced its management team will participate in November investor conferences, including Jefferies and UBS. CEO Jung E. Choi will present on ALTA3263, a KRAS-selective inhibitor in Phase 1/1b trials for colorectal and pancreatic cancers.Pulse 2.0Alterome Therapeutics Names Former Poseida CFO Johanna Mylet As Chief Financial OfficerAlterome Therapeutics appointed Johanna Mylet as CFO, overseeing financial strategy and operations. She previously served as CFO at Poseida Therapeutics, where she helped raise over $500 million. Alterome is developing KRAS-targeting therapies, including ALTA3263, and has raised over $231 million in venture capital.citybizAlterome Therapeutics Appoints Johanna Mylet as Chief Financial OfficerAlterome Therapeutics appointed Johanna Mylet as chief financial officer, bringing her experience from Poseida Therapeutics. Mylet will oversee financial strategy and capital formation as the company advances its KRAS-targeting oncology pipeline. The company has raised over $231 million in venture capital.MorningstarAlterome Therapeutics Appoints Johanna Mylet as Chief Financial OfficerAlterome Therapeutics appointed Johanna Mylet as CFO, bringing her from Poseida Therapeutics. She will lead financial strategy and capital formation as the company advances its KRAS-targeting pipeline. Mylet previously oversaw financings raising over $500 million at Poseida.BioWorldAlterome Therapeutics patents new GTPase KRAS inhibitorsAlterome Therapeutics Inc. has patented new GTPase KRAS inhibitors, which it says are potentially useful for treating cancer. The patent was filed on May 27, 2026, and the company has not disclosed further details about the inhibitors.PharmiWeb.comAlterome Therapeutics to Participate in Upcoming Investor ConferencesAlterome Therapeutics announced that members of its management team will participate in one-on-one investor meetings at the TD Cowen 46th Annual Health Care Conference in Boston (March 2–4, 2026) and the Leerink Partners 2026 Global Healthcare Conference in Miami (March 8–11, 2026). The company is a clinical-stage precision oncology biotechnology company developing alteration-specific therapeutics for cancer treatment, with two Phase 1 therapies in development. Alterome has raised more than $231 million in venture capital to date.PharmiWeb.comAlterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical OfficerAlterome Therapeutics announced the appointment of Leonardo Faoro, MD, MBA as Chief Medical Officer, bringing 16 years of oncology drug development experience, most recently as CMO at Quanta Therapeutics. Faoro will lead the Phase 1/1b clinical development of ALTA2618 (a mutation-selective AKT1 inhibitor) and ALTA3263 (a pan-KRAS inhibitor), with initial data from both programs expected in 2026. The company, which has raised over $231 million in venture capital, stated that Faoro's appointment positions it to advance these programs toward registrational studies.FinSMEsAlterome Therapeutics Raises $132M in Series B FinancingAlterome Therapeutics raised $132M in Series B funding led by Goldman Sachs Alternatives. The company will use the funds to advance its AKT1 E17K and KRAS selective inhibitors into clinical testing, expected over the next year.Pulse 2.0Alterome Therapeutics: $132 Million Closed To Pioneer Small Molecule Targeted Therapies For Cancer TreatmentsAlterome Therapeutics closed a $132 million Series B financing led by Goldman Sachs Alternatives. The funds will advance its AKT1 E17K and KRAS-selective inhibitors, with clinical testing expected within a year.AlteromeAlteromeAlterome Therapeutics announced the appointment of Jung Choi as Chief Executive Officer and Richard Heyman as Chair of the Board, alongside the appointment of Leo Faoro as Chief Medical Officer. The company also reported dosing the first patient in Phase 1 trials for its cancer therapies ALTA3263 and ALTA2618, while co-founder Eric Murphy was recognized by Goldman Sachs as a top entrepreneur.